MCID: INF023
MIFTS: 57

Inflammatory Breast Carcinoma

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Inflammatory Breast Carcinoma

MalaCards integrated aliases for Inflammatory Breast Carcinoma:

Name: Inflammatory Breast Carcinoma 12 15 17 74
Inflammatory Breast Cancer 77 54 56
Inflammatory Carcinoma of Breast 12
Inflammatory Breast Neoplasms 45
Breast Cancer, Inflammatory 54
Mastitis Carcinomatosa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6263
MeSH 45 D058922
NCIt 51 C4001
UMLS 74 C0278601

Summaries for Inflammatory Breast Carcinoma

NIH Rare Diseases : 54 Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin of the breast. This type of breast cancer is called �??inflammatory�?� because the breast often looks swollen and red, or �??inflamed.�?� The skin may also look dimpled like the skin of an orange. IBC can be difficult to diagnose because there is no lump to feel or detect on a mammogram. It is crucial to identify IBC right away because early diagnosis and treatment can greatly improve the outcome. Patients are often given a combination of treatments, including chemotherapy, surgery, and radiation therapy. Approximately one-third of individuals diagnosed with IBC will become long-term survivors. Like other types of breast cancer, IBC can occur in men, but usually at an older age than in women. Some studies have shown an association between family history of breast cancer and IBC, but more studies are needed to draw firm conclusions.

MalaCards based summary : Inflammatory Breast Carcinoma, also known as inflammatory breast cancer, is related to ovarian cancer 1 and adenocarcinoma, and has symptoms including edema, pain and peau d'orange. An important gene associated with Inflammatory Breast Carcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Pathways in cancer. The drugs leucovorin and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and lung, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased viability with paclitaxel

Disease Ontology : 12 A breast adenocarcinoma that is characterized by the clinical appearance of inflammation, with edema and redness of the breast due to pathologic plugging of the dermal lymphatics of the breast with tumor emboli.

Wikipedia : 77 Inflammatory breast cancer (IBC) is one of the most aggressive types of breast cancer that can occur in... more...

Related Diseases for Inflammatory Breast Carcinoma

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ

Diseases related to Inflammatory Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 198)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 1 29.7 CDH1 ERBB2
2 adenocarcinoma 29.5 CDH1 EGFR ERBB2
3 squamous cell carcinoma 29.4 CDH1 EGFR ERBB2
4 fallopian tube carcinoma 29.2 ERBB2 ESR1 PGR
5 breast disease 29.1 ERBB2 ESR1 PGR
6 ovarian cancer 28.7 CDH1 EGFR ERBB2 ESR1 PGR
7 breast cancer 10.6
8 breast cystic hypersecretory carcinoma 10.2 CDH1 ERBB2
9 peritoneal mesothelioma 10.1 EGFR ESR1
10 comedo carcinoma 10.1 ERBB2 ESR1
11 laryngeal disease 10.1 CDH1 EGFR
12 oropharynx cancer 10.1 CDH1 EGFR
13 pharynx cancer 10.1 CDH1 EGFR
14 bronchiolo-alveolar adenocarcinoma 10.1 CDH1 EGFR
15 breast intraductal proliferative lesion 10.1 EGFR ERBB2
16 tonsil cancer 10.1 CDH1 ERBB2
17 lymphoma 10.1
18 mastitis 10.1
19 breast squamous cell carcinoma 10.1 EGFR ERBB2
20 vestibular gland benign neoplasm 10.0 ESR1 PGR
21 bartholin's gland adenoma 10.0 ESR1 PGR
22 vulvar syringoma 10.0 ESR1 PGR
23 lung leiomyoma 10.0 ESR1 PGR
24 myoma 10.0 ESR1 PGR
25 vulvar benign neoplasm 10.0 ESR1 PGR
26 trigonitis 10.0 ESR1 PGR
27 vulvar leiomyoma 10.0 ESR1 PGR
28 acneiform dermatitis 10.0 EGFR ERBB2
29 predominantly cortical thymoma 10.0 ESR1 PGR
30 bartholin's gland benign neoplasm 10.0 ESR1 PGR
31 progesterone resistance 10.0 ESR1 PGR
32 endometrial squamous cell carcinoma 10.0 ESR1 PGR
33 cribriform carcinoma 10.0 ESR1 PGR
34 mucinous lung adenocarcinoma 10.0 EGFR ERBB2
35 endometrial mucinous adenocarcinoma 10.0 ESR1 PGR
36 adenoid basal cell carcinoma 10.0 ESR1 PGR
37 peritoneal benign neoplasm 10.0 ESR1 PGR
38 gender identity disorder 10.0 ESR1 PGR
39 gastric signet ring cell adenocarcinoma 10.0 CDH1 PGR
40 deep angioma 10.0 ESR1 PGR
41 diffuse peritoneal leiomyomatosis 10.0 ESR1 PGR
42 gallbladder adenocarcinoma 10.0 EGFR ERBB2
43 leiomyomatosis 10.0 ESR1 PGR
44 synchronous bilateral breast carcinoma 10.0 ESR1 PGR
45 female reproductive endometrioid cancer 10.0 ESR1 PGR
46 cervical carcinosarcoma 10.0 ESR1 PGR
47 adenosquamous lung carcinoma 10.0 EGFR ERBB2
48 estrogen excess 10.0 ESR1 PGR
49 colonic disease 10.0 CDH1 EGFR ESR1
50 intramuscular hemangioma 10.0 ESR1 PGR

Graphical network of the top 20 diseases related to Inflammatory Breast Carcinoma:



Diseases related to Inflammatory Breast Carcinoma

Symptoms & Phenotypes for Inflammatory Breast Carcinoma

UMLS symptoms related to Inflammatory Breast Carcinoma:


edema, pain, peau d'orange

GenomeRNAi Phenotypes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.43 CDH1 ERBB2 ESR1 FUT3 PGR PROX1
2 Decreased viability with paclitaxel GR00179-A-1 8.8 EGFR ERBB2
3 Decreased viability with paclitaxel GR00179-A-3 8.8 EGFR

MGI Mouse Phenotypes related to Inflammatory Breast Carcinoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 CDH1 EGFR ERBB2 ESR1 PGR PROX1
2 cellular MP:0005384 9.95 CDH1 EGFR ERBB2 ESR1 PGR PROX1
3 endocrine/exocrine gland MP:0005379 9.88 CDH1 EGFR ERBB2 ESR1 PGR PROX1
4 digestive/alimentary MP:0005381 9.85 CDH1 EGFR ERBB2 ESR1 PROX1
5 embryo MP:0005380 9.83 CDH1 EGFR ERBB2 ESR1 PGR
6 integument MP:0010771 9.77 CDH1 EGFR ERBB2 ESR1 PGR
7 muscle MP:0005369 9.65 EGFR ERBB2 ESR1 PGR PROX1
8 limbs/digits/tail MP:0005371 9.62 EGFR ERBB2 ESR1 PGR
9 neoplasm MP:0002006 9.55 CDH1 EGFR ERBB2 ESR1 PGR
10 normal MP:0002873 9.43 CDH1 EGFR ERBB2 ESR1 PGR PROX1
11 reproductive system MP:0005389 9.02 CDH1 EGFR ERBB2 ESR1 PGR

Drugs & Therapeutics for Inflammatory Breast Carcinoma

Drugs for Inflammatory Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 3 58-05-9 143 6006
2
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
4
Sodium Citrate Approved, Investigational Phase 3,Phase 2 68-04-2
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
7
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
8
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
9
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
10
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
11
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Pertuzumab Approved Phase 3,Phase 2,Phase 1 380610-27-5, 145040-37-5 2540
13
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 154361-50-9 60953
14
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
15
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
16
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 135968-09-1
17
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
18
Trastuzumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 180288-69-1 9903
19
Goserelin Approved Phase 2, Phase 3,Phase 3 65807-02-5 5311128 47725
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
21
Prochlorperazine Approved, Vet_approved Phase 3 1984-02-6, 58-38-8 4917
22
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
23
Palonosetron Approved, Investigational Phase 3 135729-61-2, 135729-56-5, 119904-90-4 148211
24
Fosaprepitant Approved Phase 3 172673-20-0 219090
25
Aprepitant Approved, Investigational Phase 3 170729-80-3 6918365 151165
26
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 1177-87-3
28
Adenosine Approved, Investigational Phase 3 58-61-7 60961
29
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
30
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
31
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 657181 3911
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
33
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
34
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
35
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
37 Hormone Antagonists Phase 3,Phase 2,Phase 1
38 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1
39 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
40 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Hormones Phase 3,Phase 2,Phase 1
42 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
44 Dermatologic Agents Phase 3
45 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
46 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
47 Antimetabolites Phase 3,Phase 2,Phase 1
48 Estrogen Antagonists Phase 3,Phase 2,Phase 1
49 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
50 Citrate Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer Unknown status NCT00003680 Phase 3 CMF regimen;cyclophosphamide;fluorouracil;methotrexate;tamoxifen citrate;thiotepa
2 Combination Chemotherapy in Treating Women With Breast Cancer Unknown status NCT00003679 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;tamoxifen citrate
3 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Unknown status NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
4 Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer Unknown status NCT00397761 Phase 2, Phase 3 capecitabine;paclitaxel albumin-stabilized nanoparticle formulation
5 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
6 Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer Completed NCT02324088 Phase 3 Docetaxel;Cyclophosphamide;Epirubicin
7 Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer Completed NCT00017095 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
8 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
9 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
10 S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00016406 Phase 3 cyclophosphamide;doxorubicin;paclitaxel
11 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
12 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed NCT00475085 Phase 3 aprepitant;dexamethasone;granisetron hydrochloride;palonosetron hydrochloride;prochlorperazine;placebo
13 A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed NCT02131064 Phase 3 Carboplatin;Docetaxel;Pertuzumab;Trastuzumab;Trastuzumab Emtansine
14 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
15 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Active, not recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
16 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Active, not recruiting NCT02003209 Phase 3 Aromatase Inhibition Therapy;Carboplatin;Docetaxel;Goserelin Acetate
17 Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Terminated NCT00016276 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;cyclophosphamide;paclitaxel;tamoxifen citrate
18 Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy Terminated NCT00028704 Phase 3
19 TKI258 for Metastatic Inflammatory Breast Cancer Patients Unknown status NCT01262027 Phase 2 Dovitinib
20 Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery Unknown status NCT00251329 Phase 2 neoadjuvant chemotherapy
21 A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early Unknown status NCT00957125 Phase 2 Epirubicin;Docetaxel;Bevacizumab
22 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
23 Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer Unknown status NCT00002627 Phase 1, Phase 2 carboplatin;cyclophosphamide;mesna;paclitaxel
24 Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Unknown status NCT00398489 Phase 2 anastrozole;cyclophosphamide;docetaxel;epirubicin hydrochloride;goserelin acetate;tamoxifen citrate
25 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Completed NCT00558103 Phase 2 lapatinib;Pazopanib
26 Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer Completed NCT00105950 Phase 2 lapatinib
27 Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer Completed NCT00066443 Phase 1, Phase 2 docetaxel;epirubicin hydrochloride
28 Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer Completed NCT00016549 Phase 2
29 Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer Completed NCT01325428 Phase 2 Afatinib once daily (OD);Vinorelbine Weekly
30 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193050 Phase 2 Gemcitabine;Epirubicin;Docetaxel
31 Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer Completed NCT00111787 Phase 2 Lapatinib;Paclitaxel
32 Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193206 Phase 2 Gemcitabine;Epirubicin;Albumin-bound Paclitaxel
33 Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC Completed NCT03184558 Phase 2 Bemcentinib; pembrolizumab
34 Neoadjuvant Treatment of Breast Cancer Completed NCT00254592 Phase 2 Doxorubicin;Cyclophosphamide;Carboplatin;Nab-paclitaxel;GM-CSF;Trastuzumab;Bevacizumab
35 Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Completed NCT02199418 Phase 2 Paclitaxel;Cisplatin
36 Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer Completed NCT01206881 Phase 2 pegylated liposomal doxorubicin
37 Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer Completed NCT00049114 Phase 2 doxorubicin hydrochloride;cyclophosphamide;tipifarnib
38 Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer Completed NCT00070252 Phase 1, Phase 2 Capecitabine;Docetaxel;Tipifarnib
39 A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer Completed NCT00001193 Phase 2
40 NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Completed NCT00499122 Phase 2 Cyclophosphamide;Docetaxel;Doxorubicin;NOV 002
41 Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer Completed NCT00005800 Phase 2 Docetaxel;Doxorubicin
42 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
43 Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer Completed NCT00004925 Phase 1, Phase 2 pegylated liposomal doxorubicin hydrochloride
44 Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer Completed NCT00450892 Phase 1, Phase 2 docetaxel+lapatinib;docetaxel + trastuzumab;docetaxel + trastuzumab + lapatinib
45 Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer Completed NCT00096343 Phase 2 carboplatin;paclitaxel
46 Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer Completed NCT00005798 Phase 2 Carboplatin;Cyclophosphamide;Thiotepa
47 Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00072319 Phase 2 cyclophosphamide;epirubicin hydrochloride;paclitaxel
48 Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer Completed NCT00006110 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
49 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
50 Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer Completed NCT00943410 Phase 2 Herceptin

Search NIH Clinical Center for Inflammatory Breast Carcinoma

Cochrane evidence based reviews: inflammatory breast neoplasms

Genetic Tests for Inflammatory Breast Carcinoma

Anatomical Context for Inflammatory Breast Carcinoma

MalaCards organs/tissues related to Inflammatory Breast Carcinoma:

42
Breast, Skin, Lung, Lymph Node, Bone, Prostate, Heart

Publications for Inflammatory Breast Carcinoma

Articles related to Inflammatory Breast Carcinoma:

(show top 50) (show all 769)
# Title Authors Year
1
Inflammatory breast cancer in 210 patients: A retrospective study on epidemiological, anatomo-clinical features and therapeutic results. ( 30680198 )
2019
2
Cell Permeable NBD Peptide-Modified Liposomes by Hyaluronic Acid Coating for the Synergistic Targeted Therapy of Metastatic Inflammatory Breast Cancer. ( 30668131 )
2019
3
Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer. ( 30656969 )
2019
4
Biophysical Phenotyping and Modulation of ALDH+ Inflammatory Breast Cancer Stem-Like Cells. ( 30632269 )
2019
5
Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. ( 30621221 )
2019
6
Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program. ( 30406365 )
2019
7
Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study. ( 30378451 )
2019
8
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa. ( 31006821 )
2019
9
Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer. ( 30972613 )
2019
10
Low eicosapentaenoic acid and gamma-linolenic acid levels in breast adipose tissue are associated with inflammatory breast cancer. ( 30959386 )
2019
11
Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model. ( 30952823 )
2019
12
Prevalence of germline variants in inflammatory breast cancer. ( 30933323 )
2019
13
Inflammatory breast cancer: Activation of the aryl hydrocarbon receptor and its target CYP1B1 correlates closely with Wnt5a/b-β-catenin signalling, the stem cell phenotype and disease progression. ( 30899591 )
2019
14
Synthesis, structure-activity relationship and in vitro pharmacodynamics of A-ring modified caged xanthones in a preclinical model of inflammatory breast cancer. ( 30831408 )
2019
15
Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. ( 30777104 )
2019
16
Expression signatures and roles of microRNAs in inflammatory breast cancer. ( 30733644 )
2019
17
Evaluating the incidence of inflammatory breast cancer using in population- and hospital-based cancer registries in Casablanca, Morocco. ( 31104003 )
2019
18
Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer. ( 31060575 )
2019
19
Inflammatory Breast Cancer Promotes Development of M2 Tumor-associated Macrophages and Cancer Mesenchymal Cells Through a Complex Cytokine Network. ( 31043378 )
2019
20
Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. ( 31043414 )
2019
21
The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study. ( 29967698 )
2018
22
Interleukin-18 (IL-18) is equally expressed in inflammatory breast cancer and noninflammatory locally advanced breast cancer: A possible association with chemotherapy response. ( 28766916 )
2018
23
Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. ( 28755879 )
2018
24
In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines. ( 28589573 )
2018
25
Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy. ( 30687625 )
2018
26
Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease. ( 30687062 )
2018
27
Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. ( 30584057 )
2018
28
Inflammatory Breast Cancer: A Literature Review. ( 30524636 )
2018
29
Characterization of inflammatory breast cancer: a vibrational microspectroscopy and imaging approach at the cellular and tissue level. ( 30468236 )
2018
30
Smartphone-based Compression-Induced Scope with Temperature Sensor for Inflammatory Breast Cancer Screening. ( 30441457 )
2018
31
Erratum: Zare, A. et al. RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis. Cancers, 2018, 10, 184. ( 30405083 )
2018
32
Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? ( 30307616 )
2018
33
The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome. ( 30288495 )
2018
34
The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review. ( 30278369 )
2018
35
Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. ( 30248155 )
2018
36
Homeoprotein DLX4 expression is increased in inflammatory breast cancer cases from an urban African-American population. ( 30131852 )
2018
37
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. ( 30086764 )
2018
38
Inflammatory breast cancer and chest wall disease: The oncologist perspective. ( 30032791 )
2018
39
Analysis of Hierarchical Organization in Gene Expression Networks Reveals Underlying Principles of Collective Tumor Cell Dissemination and Metastatic Aggressiveness of Inflammatory Breast Cancer. ( 30023340 )
2018
40
Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. ( 30005774 )
2018
41
Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO). ( 29976157 )
2018
42
Inflammatory Breast Cancer: What surgeons need to know. ( 29954638 )
2018
43
Inflammatory Breast Cancer: Updates on diagnosis and treatment options. ( 29945751 )
2018
44
Locally advanced non-inflammatory breast cancer may be misdiagnosed as inflammatory breast cancer. ( 29941226 )
2018
45
CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. ( 29930294 )
2018
46
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. ( 29879283 )
2018
47
RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis. ( 29874851 )
2018
48
Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. ( 29858753 )
2018
49
The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. ( 29858752 )
2018
50
Radiation therapy for inflammatory breast cancer. ( 29853159 )
2018

Variations for Inflammatory Breast Carcinoma

Expression for Inflammatory Breast Carcinoma

Search GEO for disease gene expression data for Inflammatory Breast Carcinoma.

Pathways for Inflammatory Breast Carcinoma

Pathways related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 CDH1 EGFR ERBB2 ESR1
2 12.46 CDH1 EGFR ERBB2 ESR1
3
Show member pathways
12.3 CDH1 EGFR ERBB2 ESR1
4
Show member pathways
12.22 CDH1 EGFR ERBB2
5
Show member pathways
12.02 CDH1 EGFR ERBB2 ESR1 PGR
6
Show member pathways
12.01 EGFR ERBB2 ESR1
7 11.97 EGFR ERBB2 ESR1
8 11.82 CDH1 EGFR ESR1
9
Show member pathways
11.51 EGFR ERBB2 ESR1
10 11.36 CDH1 EGFR ERBB2
11 11.33 EGFR ERBB2
12 11.29 CDH1 EGFR ERBB2
13 11.25 EGFR ESR1
14 11.2 EGFR ERBB2
15 11.14 CDH1 EGFR
16 11 EGFR ERBB2
17
Show member pathways
10.96 EGFR ERBB2 ESR1 PGR
18 10.82 CDH1 EGFR ERBB2
19 10.76 CDH1 EGFR

GO Terms for Inflammatory Breast Carcinoma

Cellular components related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basal plasma membrane GO:0009925 8.62 EGFR ERBB2

Biological processes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.81 EGFR ESR1 PGR PROX1
2 cellular response to growth factor stimulus GO:0071363 9.49 EGFR ERBB2
3 positive regulation of fibroblast proliferation GO:0048146 9.48 EGFR ESR1
4 steroid hormone mediated signaling pathway GO:0043401 9.46 ESR1 PGR
5 positive regulation of transcription, DNA-templated GO:0045893 9.46 CDH1 EGFR ESR1 PROX1
6 cellular response to epidermal growth factor stimulus GO:0071364 9.43 EGFR ERBB2
7 cellular response to estradiol stimulus GO:0071392 9.4 EGFR ESR1
8 ERBB2 signaling pathway GO:0038128 9.37 EGFR ERBB2
9 regulation of cell motility GO:2000145 9.32 EGFR ERBB2
10 regulation of ERK1 and ERK2 cascade GO:0070372 9.26 EGFR ERBB2
11 positive regulation of protein kinase B signaling GO:0051897 9.13 EGFR ERBB2 ESR1
12 negative regulation of ERBB signaling pathway GO:1901185 8.62 EGFR ERBB2

Molecular functions related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.58 EGFR ESR1 PGR
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.37 EGFR ERBB2
3 steroid hormone receptor activity GO:0003707 9.32 ESR1 PGR
4 nuclear receptor activity GO:0004879 9.26 ESR1 PGR
5 steroid binding GO:0005496 9.16 ESR1 PGR
6 identical protein binding GO:0042802 9.02 CDH1 EGFR ERBB2 ESR1 PGR
7 nitric-oxide synthase regulator activity GO:0030235 8.96 EGFR ESR1

Sources for Inflammatory Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....